Format

Send to

Choose Destination
Arthritis Res Ther. 2017 Mar 23;19(1):68. doi: 10.1186/s13075-017-1266-4.

Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies.

Author information

1
German Rheumatism Research Centre, Epidemiology Unit, Charitéplatz 1, 10117, Berlin, Germany. albrecht@drfz.de.
2
German Rheumatism Research Centre, Epidemiology Unit, Charitéplatz 1, 10117, Berlin, Germany.
3
Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany.

Abstract

Prognostic factors are used for treatment decisions in rheumatoid arthritis (RA). High disease activity, the early presence of erosions, and autoantibody positivity are the most frequently used poor prognostic factors but other features, such as functional disability, extraarticular disease, or multibiomarkers, are also assessed. Prognostic factors are incorporated in current treatment recommendations for the management of RA and are used as inclusion criteria in randomized controlled trials. They are defined heterogeneously and the relevance of a single or combined presence of poor prognostic factors remains unclear. This review summarizes the current definitions of poor prognostic factors and their use in clinical research. Perspectives on future research are also outlined.

KEYWORDS:

Outcome; Prognostic factors; Rheumatoid arthritis; Treatment

PMID:
28335797
PMCID:
PMC5364634
DOI:
10.1186/s13075-017-1266-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center